Eleven Biotherapeutics Inc. (EBIO) Shares Down 5.1%
Eleven Biotherapeutics Inc. (NASDAQ:EBIO)’s share price was down 5.1% on Wednesday . The stock traded as low as $4.40 and last traded at $4.49, with a volume of 593,570 shares trading hands. The stock had previously closed at $4.73.
The firm’s market capitalization is $73.96 million. The firm’s 50-day moving average is $4.07 and its 200 day moving average is $1.83.
Eleven Biotherapeutics (NASDAQ:EBIO) last posted its earnings results on Friday, August 12th. The biopharmaceutical company reported ($0.33) EPS for the quarter. Equities research analysts forecast that Eleven Biotherapeutics Inc. will post ($1.75) earnings per share for the current year.
In related news, major shareholder Boxer Capital, Llc sold 1,042,000 shares of the stock in a transaction on Monday, June 13th. The stock was sold at an average price of $2.74, for a total value of $2,855,080.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Eleven Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company through AMP-Rx, a protein engineering platform, is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. The Company designs, engineers and generates a pipeline of protein therapeutic candidates that target cytokines, which are central to diseases of the eye.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.